What does NeOnc Technologies Holdings, Inc. do?
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining…
What is NeOnc Technologies Holdings, Inc.'s P/E and P/B ratio?
NeOnc Technologies Holdings, Inc. has a P/E ratio of -1.4 and a P/B ratio of -4.59.
What is NeOnc Technologies Holdings, Inc.'s debt-to-equity ratio?
NeOnc Technologies Holdings, Inc. has a debt-to-equity ratio of -0.36.
How much does NeOnc Technologies Holdings, Inc. owe compared with what it owns?
NeOnc Technologies Holdings, Inc. owes $4.54 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is NeOnc Technologies Holdings, Inc.'s Positivity rank?
NeOnc Technologies Holdings, Inc. is ranked #6,375 of 6,774 companies globally and #3,646 of 4,000 in United States on PositoAI, with a Positivity Score of -17,894.
Does NeOnc Technologies Holdings, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for NeOnc Technologies Holdings, Inc..
Where can I read the latest news about NeOnc Technologies Holdings, Inc.?
Recent headlines about NeOnc Technologies Holdings, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does NeOnc Technologies Holdings, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of NeOnc Technologies Holdings, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.